7,625 Shares in AbbVie Inc. $ABBV Bought by Wealth Enhancement Trust Services Inc.

Key Points

• Wealth Enhancement Trust Services acquired a new stake of 7,625 shares of AbbVie in Q4, valued at approximately $1.742 million, while institutional investors own about 70.23% of the company.
• Corporate insiders executed significant sales—SVP David Ryan Purdue sold 5,230 shares and EVP Perry C. Siatis sold 22,381 shares—substantially reducing their individual holdings.
• Analysts' consensus is a Moderate Buy with a $253 price target, but AbbVie trades near $208 and is below its 50‑ and 200‑day moving averages, mixing bullish fundamentals with short‑term technical pressure.

Wealth Enhancement Trust Services Inc. acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 7,625 shares of the company's stock, valued at approximately $1,742,000.

Other hedge funds have also recently modified their holdings of the company. Chelsea Counsel Co. bought a new position in shares of AbbVie in the 3rd quarter worth about $26,000. Westend Capital Management LLC bought a new stake in AbbVie during the fourth quarter worth about $29,000. Texas Capital Bancshares Inc TX purchased a new stake in AbbVie in the third quarter worth about $31,000. Caitlin John LLC purchased a new stake in AbbVie in the third quarter worth about $33,000. Finally, Legacy Bridge LLC increased its stake in shares of AbbVie by 3,800.0% during the fourth quarter. Legacy Bridge LLC now owns 156 shares of the company's stock valued at $36,000 after purchasing an additional 152 shares in the last quarter. Institutional investors own 70.23% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ABBV shares. Weiss Ratings reissued a "hold (c)" rating on shares of AbbVie in a research report on Wednesday, January 21st. Barclays initiated coverage on AbbVie in a research report on Thursday, February 19th. They set an "overweight" rating and a $275.00 price objective for the company. Evercore lowered their price objective on AbbVie from $232.00 to $228.00 and set an "outperform" rating for the company in a research note on Wednesday, February 4th. BMO Capital Markets reissued an "outperform" rating on shares of AbbVie in a report on Monday, March 9th. Finally, Guggenheim increased their target price on AbbVie from $242.00 to $249.00 and gave the stock a "buy" rating in a research note on Friday, April 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $253.00.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New clinical catalysts — AbbVie’s Phase 4 head‑to‑head psoriasis study could create a meaningful commercial catalyst if results favor its therapy, supporting upside expectations for market share and pricing power. AbbVie’s Head-to-Head Psoriasis Study Sets Up New Catalyst for ABBV Investors
• Positive Sentiment: Pipeline expansion into obesity — AbbVie launched a Phase 1 trial for ABBV‑295, signaling R&D diversification beyond immunology and potential long‑term upside if early data show promise. AbbVie Steps Deeper Into Obesity Market With New Phase 1 ABBV-295 Trial
• Positive Sentiment: Real‑world HCV data could shore up legacy franchise value — retrospective safety/efficacy analyses for Glecaprevir/Pibrentasvir may support prescribing and lifecycle value. AbbVie’s Real‑World HCV Study: What G/P Safety Data Could Mean for ABBV Investors
• Positive Sentiment: Value/dividend thesis — bullish retail/analyst pieces argue AbbVie’s strong dividend yield, cash flows, and durable immunology franchises make it attractive to buy on weakness. This supports demand from income-oriented investors. Why AbbVie Is a No-Brainer Stock to Buy on the Dip
• Positive Sentiment: Commercial momentum for Skyrizi and Rinvoq — coverage notes strong sales growth for these franchises, which underpins revenue trajectory and offsets some concerns about valuation and technical weakness. AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock
• Neutral Sentiment: Market opportunity context — reports on the Middle East & Africa biosimilars market list AbbVie among players; this highlights long‑term opportunity and competitive pressures from biosimilars but is not an immediate stock mover. Middle East and Africa Biosimilars Market Trends Report 2026-2035, Profiles of AbbVie, Amgen, ...
• Neutral Sentiment: Sector reports (thyroid eye disease) and comparisons to peers — market analyses and a Pfizer vs. AbbVie piece provide framing on relative strengths and risks but add mixed conclusions rather than a clear near-term catalyst. Thyroid Eye Disease Treatment Market Research Report 2026 Featuring Amgen, ... AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit
• Negative Sentiment: Technical pressure — multiple outlets highlight ABBV trading below its 50‑ and 200‑day moving averages, a short‑term bearish signal that can trigger further selling by technical traders and funds. That is likely the primary driver of today’s downward price move. AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock

Insiders Place Their Bets

In related news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company's stock, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company's stock, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.06% of the company's stock.

AbbVie Stock Down 0.3%

NYSE:ABBV opened at $208.29 on Friday. The stock has a market cap of $368.28 billion, a price-to-earnings ratio of 88.26, a PEG ratio of 0.74 and a beta of 0.38. The company's 50 day moving average price is $219.00 and its 200-day moving average price is $223.52. AbbVie Inc. has a 52 week low of $168.54 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts' consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm's revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the previous year, the business earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's dividend payout ratio is presently 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.